l-DOPA therapy remains the gold standard treatment for PD. However, l-DOPA chronic administration does not cure PD. In the contrary, it is related with motor complications including l-DOPAinduced dyskinesia (LID) [6, 23] . Once it has been established, dyskinesia will be induced after each l-DOPA administration, limiting the therapeutic benefit over time. Evidence from rodent models of PD and dyskinesia provide information to better understand the molecular mechanisms underlying the development of LID [9, 27] . The combined effects of progressive dopamine (DA) cell loss in substantia nigra pars compacta (SNpc) associated with pulsatile stimulation of dopaminergic receptors [34, 35] are thought to be the major determinant of l-DOPA liability in the induction of dyskinesia.
NOS inhibitors appeared as a potential pharmacological approach for the treatment of LID [14] . The association of l-DOPA and NOS inhibitors (7-NI, NG-nitro-l-Arginine -l-NOARG, NGnitro-l-Arginine-methyl ester (l-NAME, both nonselective NOS inhibitor), reduced established LID with no observable motor impairment in rodents [36, 37, 46] and non-human primates [22, 50] . Sub chronic administration of 7-NI reduced AIMs indicating that prolonged administration of 7-NI does not produce tolerance [33] . Chronic administration of l-NAME but not aminoguanidine, decreased LID in 6-OHDA-lesioned rats [46] .
The transcription factor FosB/ FosB is increased in the rodent DA-depleted striatum following l-DOPA treatment [1, 8, 11, 32, 36, 38] . There is a similar pattern of FosB/ FosB expression in patients [28, 47] and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys [4] . Following chronic l-DOPA exposure, FosB/ FosB is selectively expressed in NADPH-d/NOS-positive striatal neurons in parkinsonian rodents [11, 38] . FosB/ FosB may regulate the expression of genes that induce the pathogenic cascade related to the altered motor responses to l-DOPA [8] . The foremost mechanism of FosB/ FosB expression in striatal NOS-expressing neurons during LIDs is not known.
Here we confirm that a single application of 7-NI mitigate preestablished LID in 6-OHDA-lesioned rat.
Experiments were conducted according to the principles and procedures described by the guidelines for the care and use of mammals in neuroscience and behavioral research (ILAR, USA). Male Wistar rats (200-250 g) were submitted to stereotaxic surgery for microinjection of 6-OHDA as described before [37] . Control animals received saline microinjections (sham-operated). To assess lesion intensity, rats were tested for apomorphine (Sigma-Aldrich, USA, 0.5 mg/kg, s.c.) induced rotation. 6-OHDA-lesioned rats presenting more than 90 rotations/45 min were included in the study [37] . At the end of experiment, the extension of the lesion was verified by immunohistochemistry for tyrosine hydroxylase (TH) at the SNpc.
6-OHDA-lesioned rats (n = 10) received daily administration of l-DOPA (30 mg/kg/day + benserazide 7.5 mg/kg/day, Prolopa dispersive, Hoffman-LaRoche, Brazil) for 22 days. Axial, limb, orofacial and locomotor AIMs were evaluated according to a rat dyskinesia scale [10, 29, 49] on the 1st, 7th, 14th, 21st and 22nd day of treatment. Each rat was scored on a severity scale from 0 to 4 in each of the four subtypes of AIMs at 1 and 2 h after l-DOPA intake during 1 min [37] . On the 22nd day of treatment 6-OHDA-lesioned rats were divided into equivalent sub-groups according to the AIMs scores obtained on day 21st. Each subgroup received, 30 min before l-DOPA, either 7-NI (Sigma-Aldrich, USA, 30 mg/kg, "7-NI/L-DOPA", n = 6) or its vehicle (50% polyethylene glycol-saline solution, "Veh/L-DOPA", n = 4). 6-OHDA-lesioned (n = 6) and sham-operated (n = 6) animals that receive no treatment of any kind were used as controls. 7-NI effects were obtained by between comparisons of AIMs on 22nd. Additionally, motor coordination and balance were tested using a rota-rod (Ugo Basile, Rota-rod 7750, Italy) to exclude any possibility of 7-NI interference in motor behavior. Rotarod tests (speed of the acceleration from 4 to 40 rpm over a 300 s period) were performed 1 and 2 h after l-DOPA intake [15] . Because there was no statistical difference between time measurement (p > 0.05, paired "t" test) results are expressed as the average latency time spent on the rod.
Two hours after L-DOPA administration on day 22nd rats were perfused transcardiacally with 250 ml of cold saline followed by 400 ml of 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA) in 0.1 M phosphate buffer (pH 7.4). Brains were postfixed at 4 • C C for 1 h in the above fixative and cryoprotected at 4 • C overnight in 0.1 M phosphate buffer (pH 7.4) with 30% sucrose.
Immunohistochemistry was performed in coronal sections (25 m) through the SNpc and striatum using a standard peroxidase based method [19] . SNpc and striatal sections were incubated, respectively, with primary rabbit polyclonal anti-TH (1:2000, Pel Freez, Rogers, AR, USA) and rabbit polyclonal anti-FosB/ FosB (1:1000, Santa Cruz Biotechnology, USA).
Quantifications were carried out using three sections per animal in a light microscope (Leica DMRB) equipped with a video camera (Leica DFC420). Neuroanatomical sites were identified using the atlas of Paxinos and Watson [39] and the analysis was done using the software ImageJ (http://rsb.info.nih.gov). DA-depletion was analyzed [35] in SNpc (AP: −5.8 mm and AP: −6.04 mm, from Bregma) [39] . FosB/ Fos-B positive cells in the striatum were analyzed at levels AP: 0.48 mm and AP: −0.92 mm (from bregma) [39] corresponding, respectively, to rostro-medial and caudal portions of striatum. Analysis was performed in every fifth section (i.e. separated by 125 m). In the striatum, quantification were done within two adjacent areas of 286 m × 214 m (40X) and the total number of neurons were averaged and expressed in number of cells/0.5 mm 2 . At rostro-medial level (AP: 0.48 mm), four quadrants within the dorso-medial, ventro-medial, dorso-lateral and ventro-lateral regions were analyzed. At caudal levels (AP: −0.92 mm) striatum was analyzed at dorso-lateral and ventrolateral quadrants. Because there was no difference between dorsoand ventro-medial quadrants, as well dorso-and ventro-lateral quadrants, the number of FosB/ Fos-B positive nuclei in these regions was averaged and data is expressed in terms of "medial" and "lateral" striatum.
AIMs scores collected during chronic l-DOPA treatment were analyzed by Friedman test followed by a Wilcoxon post hoc. Effects of 7-NI on AIMs and rotarod performance were analyzed using Mann-Whitney test. The 7-NI effects in the FosB/ FosB expression among the different sites of striatum were analyzed by two-way ANOVA, with repeated measures followed by a Duncan's post hoc. Comparisons were done for treatments (Veh/l-DOPA and 7-NI/l-DOPA) being side (lesioned-and unlesioned side) the repeated measure. Statistical significance level was set at p < 0.05.
TH-immunostaining indicated almost complete degeneration (>90%) of the TH-positive cell/fiber in the lesioned SNpc and striatum. The development of axial, limb, orofacial and locomotive AIMs (Fig. 1A and B) increased during chronic l-DOPA treatment (p < 0.05). Corroborating our previous results, acute 7-NI (30 mg/kg) attenuated l-DOPA-induced axial, limb and orofacial AIMs ( Fig. 1C ; p < 0.05) as well as locomotive AIMs scores ( Fig. 1D ; p < 0.05). 7-NI prevented l-DOPA-induced motor impairment in the rotarod by increasing animal ability to stay in the rod ( Fig. 1D ; p < 0.05). The ability of the rat stay in the rotarod was inversely correlated with AIMs incidence (Fig. 1E and F) .
As described before by Western blot [36] 6-OHDA induced an increase in the FosB/ Fos-B in the lesioned striatum as compared to sham-operated animals (data not shown).
At the medial portion of the lesioned striatum (bregma 0.48 mm, Fig. 2A ), l-DOPA induced a significant increase in the Fos-B/ Fos-B staining (1.6 fold) when compared to the unlesioned striatum At caudal level (bregma −0.92 mm, Fig. 2C ) a significant increment (≈1.9 fold) in the Fos-B/ Fos-B staining was also observed The result of this study support that chronic l-DOPA treatment of 6-OHDA-lesioned rats induced an increase in the FosB/ Fos-B-immunopositive neurons in the dopamine depleted striatum, confirming others and ours previous description [36] . This overexpression was attenuated in lateral portion of striatum by one single injection of 7-NI, 30 min before l-DOPA application (increase of more than 43 fold followed by a 54% reduction).
In addition, it indicates an association between axial, limb and orolingual AIMs with FosB/ Fos-B labeling in the sensorimotor (lateral) part of the striatum [1] . Other studies demonstrated that lateral striatum influence the orofacial and limb movements [5, 7, 16, 17, 24, 26, 41, 42] . In comparison, locomotive AIMs would mainly be linked to medial striatum [1, 16] . Therefore, FosB/ Fos-B-expression and the action of 7-NI in the lesioned striatum are related with neuroanatomical projections. [39] . Increments in Fos-B/ Fos-B-positive nuclei were observed in lesioned striatum of dyskinetic animals (G-I, "Veh/l-DOPA"). 7-NI was able to reduce Fos-B/ Fos-B staining (J-L, "Veh/l-DOPA") although statistically significance was observed only for regions analyzed at bregma 0.48 mm. Scale bar: 100 m.
Nitric oxide (NO) plays a main role in motor control within the central nervous system as shown by pharmacological blockage and knockdown of nNOS enzyme [13, 14] . Within the striatum, NO has a needed role in striatal output pathways by interacting with other neurotransmitter systems [48] . Dopamine D1-like receptor activation [44] and electrical stimulation of nigrostriatal neurons increased NO efflux in the striatum [43] . These studies indicate a dopamine modulation of striatal nNOS enzyme/interneuron activity via dopamine D1-like and D2-like receptor dependent mechanism [43] [44] [45] . Finally, data from our group [33, 36, 37, 50] and others [22, 46] that pharmacological blockage of NOS enzyme was able to attenuate LID without interfering with beneficial l-DOPA motor effects.
Maintenance of dyskinesia implies in plastic changes with longterm modifications of the basal ganglia network. The NO system undergoes plasticity after dopamine depletion but the relation between NO and LID is not understood yet [14, 30, 40] . Immediate early gene expression is proposed to be a mediator of long-term response of the brain to drugs, stress and other chronic events [21] , including l-DOPA administration [2, 8, 11, 32, 38] . FosB/ FosBrelated proteins are proposed to be the main postsynaptic striatal marker for dyskinesia in rodent model of PD [1, 8] . The importance of FosB/ FosB up regulation as a determinant of LID is supported by the anti-dyskinetic effect of treatment blocking either striatal FosB/ FosB induction during chronic l-DOPA administration [1] or dyskinetic effect induced by the exacerbate expression of the protein [8] . Our results suggest that 7-NI attenuation of LID in parkinsonian rodents is, at least in part, through blocking the induction of FosB/ FosB expression.
Following dopamine depletion and LID induction, striatal D1-like receptor undergoes redistribution to the postsynaptic membrane and cytoplasmic compartments [3, 20, 31] . FosB/ FosB is expressed in dynorphin-positive striatal neurons [1, 25] , which express the dopamine D1-like receptor and project into the direct output pathway [18] . LID is blocked in the D1-like but not D2-like receptors knockout mice with striatal DA depletion induced by 6-OHDA [12] . It suggests that D1-like receptor stimulation is essential for the development of LID and the expression of the molecular markers such as FosB/ FosB [12] . According to these results, it is possible that the attenuation of LID induced by 7-NI involves preferentially striatal neurons of the direct pathway which express the D1-like dopaminergic receptors. More experiments are needed to reveal the specific type of striatal neurons.
In conclusion, we show the reduction of LID in the 6-OHDAlesioned rat striatum by nNOS inhibitor, associated with the attenuation of striatal FosB/ FosB expression. Taken together, the data supports the evidence that the anti-dyskinetic effect of NO inhibitors is, at least in part, linked to the expression of the transcription factor FosB/ FosB.
